{
    "clinical_study": {
        "@rank": "160",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 13, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04343144"
        },
        "id_info": {
            "org_study_id": "APHP200389-5",
            "nct_id": "NCT04343144"
        },
        "brief_title": "CORIMUNO19-NIVO: TRIAL EVALUATING EFFICACY and SAFETY OF NIVOLUMAB (OPDIVO\u00ae) IN PATIENTS WITH COVID-19 INFECTION, NESTED IN THE CORIMUNO-19 COHORT",
        "acronym": "CORIMUNO-NIVO",
        "official_title": "Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19-Nivolumab Trial",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris",
                "agency_class": "Other"
            }
        },
        "source": "Assistance Publique - H\u00f4pitaux de Paris",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "It appears interesting to use nivolumab in severe patients infected with SARS-CoV-2 requiring\n      hospitalization in conventional unit or in ICU.\n\n      This protocol CORIMUNO19-NIVO therefore, will evaluate the efficacy and safety of OPTIVO\u00ae\n      (nivolumab) COVID-19 patients hospitalized in conventional unit.\n\n      The purpose of this study is to show the efficacy of nivolumab in patients with COVID-19 in\n      combination with standard treatments.\n\n      A phase 2 randomized open trial will evaluate the efficacy and safety of optivo\u00ae (nivolumab)\n      alone versus standard of care (SoC) in patients hospitalized in conventional units.\n\n      Patients will be randomly allocated 1:1 to either nivolumab or SoC."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 15, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "September 30, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "July 31, 2020"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "intervention_model_description": "2 parallels arms randomized open-label multi center clinical trial",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": {
            "measure": "Time to clinical improvement",
            "time_frame": "day 14",
            "description": "the time required for clinical improvement, defined as the time elapsed between randomization and a two-point improvement on an ordinal scale with seven categories (WHO scale), or the discharge alive from hospital, whatever occurred first"
        },
        "secondary_outcome": [
            {
                "measure": "Overall survival",
                "time_frame": "day 28"
            },
            {
                "measure": "Overall survival",
                "time_frame": "day 90"
            },
            {
                "measure": "Cumulative incidence of ICU admission",
                "time_frame": "day 28"
            },
            {
                "measure": "Length of hospital stay",
                "time_frame": "day 90"
            },
            {
                "measure": "Positive nasal PCR",
                "time_frame": "day 7"
            },
            {
                "measure": "Incidence of adverse events",
                "time_frame": "day 28"
            },
            {
                "measure": "Incidence of grade 3-4 adverse events",
                "time_frame": "day 28",
                "description": "according to CTC AE-4.03"
            },
            {
                "measure": "WHO scale",
                "time_frame": "day 4, 7 and 14"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "92"
        },
        "condition": "COVID19- Infection With SARS-CoV-2 Virus",
        "arm_group": [
            {
                "arm_group_label": "Nivolumab",
                "arm_group_type": "Experimental"
            },
            {
                "arm_group_label": "Standard of Card",
                "arm_group_type": "No Intervention"
            }
        ],
        "intervention": {
            "intervention_type": "Drug",
            "intervention_name": "Nivolumab Injection",
            "description": "Treatment consists of an infusion of OPDIVO\u00ae 3mg/kg on day 1 (D1).",
            "arm_group_label": "Nivolumab"
        },
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults (men and women) age over 18 years old\n\n          -  At least one nasal swab positive for COVID-19 detected by PCR, maximum 7 days prior to\n             treatment\n\n          -  Viral pneumonia confirmed by TDM scan\n\n          -  Patients meeting all of the following 3 criteria:\n\n               -  Requiring more than 3L/min of oxygen\n\n               -  WHO progression scale = 5\n\n               -  No NIV or High flow\n\n        Exclusion Criteria:\n\n          -  Patients with active cancer and immunocopromised patients\n\n          -  Known hypersensitivity to nivolumab or to any of their excipients.\n\n          -  Pregnancy\n\n          -  Patient with an autoimmune or inflammatory disease (including but not limited to:\n             Crohn's Disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus,\n             Grave's disease). Patients with thyroiditis or vitiligo only could be included.\n\n          -  Patient with a history of thymoma\n\n          -  Patient with a history of solid organ transplantation or a bone marrow transplantation\n\n          -  Patients treated with immune checkpoint inhibitors 3 months prior to the study\n\n          -  Patients who had a history of grade 3 or 4 immune-related adverse events with a\n             previous treatment with immune-checkpoint inhibtors\n\n          -  Patients requiring ICU based on Criteria of severity of COVID pneumopathy\n\n          -  Respiratory failure requiring mechanical ventilation or extracorporeal membrane\n             oxygenation"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_contact": {
            "last_name": "Jacques Cadranel, MD PhD",
            "phone": "1 56 01 66 73",
            "phone_ext": "+33",
            "email": "jacques.cadranel@aphp.fr"
        },
        "location": {
            "facility": {
                "name": "Pneumologie h\u00f4pital Tenon",
                "address": {
                    "city": "Paris",
                    "zip": "75019",
                    "country": "France"
                }
            },
            "contact": {
                "last_name": "Jacques Cadranel, MD PhD",
                "phone": "01 56 01 66 73",
                "email": "jacques.cadranel@aphp.fr"
            }
        },
        "location_countries": {
            "country": "France"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "April 9, 2020",
        "study_first_submitted_qc": "April 9, 2020",
        "study_first_posted": {
            "@type": "Estimate",
            "#text": "April 13, 2020"
        },
        "last_update_submitted": "April 9, 2020",
        "last_update_submitted_qc": "April 9, 2020",
        "last_update_posted": {
            "@type": "Estimate",
            "#text": "April 13, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "condition_browse": {
            "mesh_term": "Infection"
        },
        "intervention_browse": {
            "mesh_term": "Nivolumab"
        }
    }
}